Kazia Therapeutics (KZIA) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Stablecoin Development (SDEV) over the past year, gaining 23.2% versus a loss of 66.8%. Over five years, KZIA leads with a -98.3% price change compared with -99.9% for SDEV. Stablecoin Development is the larger company by market cap ($103.0 million vs $100.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | SDEV |
|---|---|---|
| Share price | $8.82 | $1.99 |
| Market cap | $100.79M | $102.99M |
| 1-day change | -5.06% | -28.42% |
| YTD return | +28.01% | -92.94% |
| 1-year return | +23.18% | -66.83% |
| 5-year return | -98.32% | -99.94% |
| EPS (TTM) | $-6.85 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $99.75 |
| 52-week low | $4.86 | $0.78 |
| Distance from 52-week high | -49.31% | -98.01% |
| Analyst consensus | none | — |
| Avg. price target upside | +220.41% | — |
| Average volume | 262.15K | 11.42M |
| Shares outstanding | 11.43M | 51.75M |
| Employees | 6 | 2 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed SDEV by 90.0 percentage points over the past year.
- The two companies sit in different sectors: Kazia Therapeutics in Healthcare and Stablecoin Development in Health Care.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Healthcare · Biotechnology · 6 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
KZIA vs SDEV FAQ
Which is bigger, Kazia Therapeutics or Stablecoin Development?
Stablecoin Development (SDEV) is larger, with a market capitalization of $102.99M compared with $100.79M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, KZIA or SDEV?
KZIA returned +23.18% over the past 12 months, compared with -66.83% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and Stablecoin Development in the same industry?
No. Kazia Therapeutics is in the Healthcare sector, while Stablecoin Development is in Health Care.